

**Contact:** John Finn  
President, Rx<sup>3</sup> Pharmaceuticals  
(858) 452-0370  
[jfinn@rx3pharma.com](mailto:jfinn@rx3pharma.com)

## **Rx<sup>3</sup> Pharmaceuticals Expands Management Team**

### ***Anti-microbial company hires Chief Financial Officer to raise VC funds***

San Diego, CA, January 3, 2005 – Rx<sup>3</sup> Pharmaceuticals, Inc., a drug discovery company, announced today that it has hired John P. Schmid to serve as its Chief Financial Officer. Mr. Schmid was previously co-founder and CFO of GeneFormatics as well as the first CFO of Endonetics. Both firms were backed by major venture capital investors. Over the past seven months, Mr. Schmid has served as an adviser and consultant to Rx<sup>3</sup> in forming, capitalizing, and launching the Company.

“We are so pleased to have John join our team to accelerate the Company’s development and capitalization,” said John Finn, President of Rx<sup>3</sup> Pharmaceuticals. “He played a major role in the formation of the Company and has been a valuable contributor since our inception. We are excited to have him working side by side with us as a colleague.”

John Schmid said, “Having been involved in launching three companies previously, I can say that this company, its team, and its technology are much further developed than most start-ups. It’s a pleasure to be in the company of such experienced colleagues.”

### **About Rx<sup>3</sup> Pharmaceuticals**

Rx<sup>3</sup> Pharmaceuticals is a drug discovery company applying its structure-based drug design technologies to antimicrobial programs. These programs target novel proteins in validated pathways. Rx<sup>3</sup>’s discovery team has advanced anti-bacterial programs into late stage drug discovery and expects to identify development candidates in 2006. For more information, visit [www.rx3pharma.com](http://www.rx3pharma.com).

**Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements and are subject to risks and uncertainties that may cause actual results to differ materially from the results described in, or implied by, the forward-looking statements. Rx<sup>3</sup> disclaims any intent or obligation to update these forward-looking statements.**

###